Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936014793> ?p ?o ?g. }
- W2936014793 endingPage "e0215298" @default.
- W2936014793 startingPage "e0215298" @default.
- W2936014793 abstract "Myostatin (MSTN) negatively regulates skeletal muscle growth, and its activity is inhibited by the binding of MSTN propeptide (MSTNpro), the N-terminal domain of proMSTN that is proteolytically cleaved from the proMSTN. Partial sequences from the N-terminal side of MSTNpro have shown to be sufficient to inhibit MSTN activity. In this study, to determine the minimum size of flatfish MSTNpro for MSTN inhibition, various truncated forms of flatfish MSTNpro with N-terminal maltose binding protein (MBP) fusion were expressed in E. coli and purified. MSTNpro regions consisting of residues 45-68, -69, and -70 with MBP fusion suppressed MSTN activity with a potency comparable to that of full-sequence flatfish MSTNpro in a pGL3-(CAGA)12-luciferase reporter assay. Even though the MSTN-inhibitory potency was about 1,000-fold lower, the flatfish MSTNpro region containing residues 45-65 (MBP-Pro45-65) showed MSTN-inhibitory capacity but not the MBP-Pro45-64, indicating that the region 45-65 is the minimum domain required for MSTN binding and suppression of its activity. To examine the in vivo effect of MBP-fused, truncated flatfish MSTNpro, MBP-Pro45-70-His6 (20 mg/kg body wt) was subcutaneously injected 5 times for 14 days in mice. Body wt gain and bone mass were not affected by the administration. Grip strength and swimming time were significantly enhanced at 7 d after the administration. At 14 d, the effect on grip strength disappeared, and the extent of the effect on swimming time significantly diminished. The presence of antibody against MBP-Pro45-70-His6 was observed at both 7 and 14 d after the administration with the titer value at 14 d being much greater than that at 7 d, suggesting that antibodies against MBP-Pro45-70-His6 neutralized the MSTN-inhibitory effect of MBP-Pro45-70-His6. We, thus, examined the MSTN-inhibitory capacity and in vivo effect of flatfish MSTNpro region 45-65 peptide (Pep45-65-NH2), which was predicted to have no immunogenicity in silico analysis. Pep45-65-NH2 suppressed MSTN activity with a potency similar to that of MBP-Pro45-65 but did not suppress GDF11, or activin A. Pep45-65-NH2 blocked MSTN-induced Smad2 phosphorylation in HepG2 cells. The administration of Pep45-65 (20 mg/kg body wt, 5 times for 2 weeks) increased the body wt gain with a greater gain at 14 d than at 7 d and muscle wt. Grip strength and swimming time were also significantly enhanced by the administration. Antibody titer against Pep45-65 was not detected. In conclusion, current results indicate that MSTN-inhibitory proteins with heterologous fusion partner may not be effective in suppressing MSTN activity in vivo due to an immune response against the proteins. Current results also show that the region of flatfish MSTNpro consisting of 45-65 (Pep45-65) can suppress mouse MSTN activity and increase muscle mass and function without invoking an immune response, implying that Pep45-65 would be a potential agent to enhance skeletal muscle growth and function in animals or to treat muscle atrophy caused by various clinical conditions." @default.
- W2936014793 created "2019-04-25" @default.
- W2936014793 creator A5026168417 @default.
- W2936014793 creator A5048853406 @default.
- W2936014793 creator A5050292482 @default.
- W2936014793 creator A5052100533 @default.
- W2936014793 creator A5065629591 @default.
- W2936014793 creator A5068344018 @default.
- W2936014793 creator A5083180933 @default.
- W2936014793 date "2019-04-18" @default.
- W2936014793 modified "2023-10-17" @default.
- W2936014793 title "Identification of the minimum region of flatfish myostatin propeptide (Pep45-65) for myostatin inhibition and its potential to enhance muscle growth and performance in animals" @default.
- W2936014793 cites W1058527918 @default.
- W2936014793 cites W1951890910 @default.
- W2936014793 cites W1966581336 @default.
- W2936014793 cites W1974310129 @default.
- W2936014793 cites W1974949460 @default.
- W2936014793 cites W1982626985 @default.
- W2936014793 cites W1987729136 @default.
- W2936014793 cites W1994270208 @default.
- W2936014793 cites W2009324447 @default.
- W2936014793 cites W2015611034 @default.
- W2936014793 cites W2018289835 @default.
- W2936014793 cites W2028966038 @default.
- W2936014793 cites W2034074403 @default.
- W2936014793 cites W2040703008 @default.
- W2936014793 cites W2051816002 @default.
- W2936014793 cites W2053079324 @default.
- W2936014793 cites W2053710837 @default.
- W2936014793 cites W2054368198 @default.
- W2936014793 cites W2056485354 @default.
- W2936014793 cites W2061495510 @default.
- W2936014793 cites W2066280893 @default.
- W2936014793 cites W2066735808 @default.
- W2936014793 cites W2067181473 @default.
- W2936014793 cites W2074063262 @default.
- W2936014793 cites W2083700023 @default.
- W2936014793 cites W2084480543 @default.
- W2936014793 cites W2088227751 @default.
- W2936014793 cites W2089683126 @default.
- W2936014793 cites W2100837269 @default.
- W2936014793 cites W2102638170 @default.
- W2936014793 cites W2104717998 @default.
- W2936014793 cites W2105608476 @default.
- W2936014793 cites W2108676843 @default.
- W2936014793 cites W2115099835 @default.
- W2936014793 cites W2124205424 @default.
- W2936014793 cites W2133828201 @default.
- W2936014793 cites W2136851399 @default.
- W2936014793 cites W2140649717 @default.
- W2936014793 cites W2141923361 @default.
- W2936014793 cites W2149993139 @default.
- W2936014793 cites W2159974512 @default.
- W2936014793 cites W2160199212 @default.
- W2936014793 cites W2165995731 @default.
- W2936014793 cites W2166947475 @default.
- W2936014793 cites W2235165689 @default.
- W2936014793 cites W2292617264 @default.
- W2936014793 cites W2335025342 @default.
- W2936014793 cites W2504764764 @default.
- W2936014793 cites W2507871962 @default.
- W2936014793 cites W2549739395 @default.
- W2936014793 cites W2601491516 @default.
- W2936014793 cites W2604228136 @default.
- W2936014793 cites W2604942790 @default.
- W2936014793 cites W2697458340 @default.
- W2936014793 cites W2731310808 @default.
- W2936014793 cites W2767554184 @default.
- W2936014793 cites W4239540302 @default.
- W2936014793 doi "https://doi.org/10.1371/journal.pone.0215298" @default.
- W2936014793 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6472743" @default.
- W2936014793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30998775" @default.
- W2936014793 hasPublicationYear "2019" @default.
- W2936014793 type Work @default.
- W2936014793 sameAs 2936014793 @default.
- W2936014793 citedByCount "5" @default.
- W2936014793 countsByYear W29360147932020 @default.
- W2936014793 countsByYear W29360147932021 @default.
- W2936014793 crossrefType "journal-article" @default.
- W2936014793 hasAuthorship W2936014793A5026168417 @default.
- W2936014793 hasAuthorship W2936014793A5048853406 @default.
- W2936014793 hasAuthorship W2936014793A5050292482 @default.
- W2936014793 hasAuthorship W2936014793A5052100533 @default.
- W2936014793 hasAuthorship W2936014793A5065629591 @default.
- W2936014793 hasAuthorship W2936014793A5068344018 @default.
- W2936014793 hasAuthorship W2936014793A5083180933 @default.
- W2936014793 hasBestOaLocation W29360147931 @default.
- W2936014793 hasConcept C104317684 @default.
- W2936014793 hasConcept C123894998 @default.
- W2936014793 hasConcept C126322002 @default.
- W2936014793 hasConcept C134018914 @default.
- W2936014793 hasConcept C153911025 @default.
- W2936014793 hasConcept C167414201 @default.
- W2936014793 hasConcept C185592680 @default.
- W2936014793 hasConcept C202751555 @default.
- W2936014793 hasConcept C207001950 @default.
- W2936014793 hasConcept C2777488582 @default.
- W2936014793 hasConcept C2779950014 @default.